Compare CDMOs with formulation development expertise for oral, injectable, topical, and inhalation dosage forms. Filter by technology platform, therapeutic area, and regulatory support.
621 companies listed
Is your molecule barely soluble? You're not alone. Most new chemical entities in the pipeline are, and formulation is where that problem gets solved or shelved. Formulation development takes an API and makes it stable, absorbable, and manufacturable at scale. It starts with pre-formulation (solubility, stability, excipient compatibility), and it sets the ceiling on your drug's clinical performance. Get it wrong and a promising molecule stalls. The capability that separates a real formulation CDMO from a general one is bioavailability enhancement. Ask what enabling platforms they run in-house: spray-dried dispersions, hot melt extrusion, nano-milling, lipid-based systems, cyclodextrin complexation. One platform isn't enough, because the right approach depends on your compound's physicochemistry. Engage early, ideally in late discovery. Late-stage formulation changes are expensive, and they eat months. 621 CDMOs here offer formulation development. Compare them by platform, dosage form, and therapeutic area.
Formulation development transforms an API into a stable, bioavailable, and manufacturable dosage form. It begins with pre-formulation studies (solubility, stability, compatibility) and progresses through prototype development, optimization, and scale-up. The formulation defines the drug product's clinical performance, and poor formulation choices can doom an otherwise promising molecule.
Bioavailability enhancement is the fastest-growing formulation challenge. An estimated 70-90% of new chemical entities in development pipelines have poor aqueous solubility. CDMOs with expertise in enabling technologies -- amorphous solid dispersions (spray drying, hot melt extrusion), lipid-based drug delivery systems, nanoparticle milling, and complexation -- can rescue molecules that would otherwise fail.
Portugal
Grupo Azevedos, operating through its Sofarimex manufacturing unit, is a Portuguese CDMO specializing in freeze-dried injectables and sterile eye drops, with over 20 years of contract manufacturing experience. The company manufactures pharmaceutical medicines and health products for third parties across non-sterile solid, semi-solid, and liquid forms, as well as sterile products, and holds manufacturing licenses from INFARMED and multiple international authorities.
Portugal
Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970, with an industrial unit that has provided contract manufacturing services for over 20 years. The company manufactures non-sterile solid, semi-solid, and liquid pharmaceutical products for third-party clients, offering turnkey and custom services including bulk manufacturing, packaging, analytical release, and scale-up support.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.